Fundamental Analysis of TANGO THERAPEUTICS INC(NASDAQ:TNGX) stock

Fundamental Rating

TNGX gets a fundamental rating of 3 out of 10. The analysis compared the fundamentals against 564 industry peers in the Biotechnology industry. TNGX has a great financial health rating, but its profitability evaluates not so good. TNGX does not seem to be growing, but still is valued expensively.

Quickly go to:

1. Profitability

1.1 Basic Checks

TNGX had negative earnings in the past year.

TNGX had a negative operating cash flow in the past year.

TNGX had negative earnings in each of the past 5 years.

TNGX had a negative operating cash flow in each of the past 5 years.

1.2 Ratios

Looking at the Return On Assets, with a value of -30.54%, TNGX is in the better half of the industry, outperforming 66.67% of the companies in the same industry.

The Return On Equity of TNGX (-47.03%) is better than 67.74% of its industry peers.

		Industry Rank	Sector Rank
ROA	-30.54%
ROE	-47.03%
ROIC	N/A

ROA(3y)-20.57%

ROA(5y)N/A

ROE(3y)-33.48%

ROE(5y)N/A

ROIC(3y)N/A

ROIC(5y)N/A

1.3 Margins

TNGX does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.

		Industry Rank	Sector Rank
OM	N/A
PM (TTM)	N/A
GM	N/A

OM growth 3YN/A

OM growth 5YN/A

PM growth 3YN/A

PM growth 5YN/A

GM growth 3YN/A

GM growth 5YN/A

More info and screens

ROA

ROE

ROIC

Operating and Profit Margin

Show most profitable peers

2. Health

2.1 Basic Checks

TNGX does not have a ROIC to compare to the WACC, probably because it is not profitable.

Compared to 1 year ago, TNGX has more shares outstanding

TNGX has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.

2.2 Solvency

Based on the Altman-Z score of -0.18, we must say that TNGX is in the distress zone and has some risk of bankruptcy.

With a decent Altman-Z score value of -0.18, TNGX is doing good in the industry, outperforming 60.78% of the companies in the same industry.

There is no outstanding debt for TNGX. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.

		Industry Rank	Sector Rank
Debt/Equity	0
Debt/FCF	N/A
Altman-Z	-0.18

ROIC/WACCN/A

WACC10.35%

2.3 Liquidity

TNGX has a Current Ratio of 7.49. This indicates that TNGX is financially healthy and has no problem in meeting its short term obligations.

The Current ratio of TNGX (7.49) is better than 69.34% of its industry peers.

TNGX has a Quick Ratio of 7.49. This indicates that TNGX is financially healthy and has no problem in meeting its short term obligations.

TNGX has a better Quick ratio (7.49) than 69.52% of its industry peers.

		Industry Rank	Sector Rank
Current Ratio	7.49
Quick Ratio	7.49

More info and screens

WACC

Debt/Equity

How to determine the health of a company

Altman-Z score

Show peers with great health

3. Growth

3.1 Past

TNGX shows a slight negative growth in Earnings Per Share. In the last year, the EPS has decreased by -6.31%.

Looking at the last year, TNGX shows a very strong growth in Revenue. The Revenue has grown by 46.93%.

EPS 1Y (TTM)-6.31%

EPS 3YN/A

EPS 5YN/A

EPS Q2Q%-17.39%

Revenue 1Y (TTM)46.93%

Revenue growth 3YN/A

Revenue growth 5YN/A

Sales Q2Q%8.18%

3.2 Future

TNGX is expected to show a very negative growth in Earnings Per Share. In the coming years, the EPS will decrease by -10.08% yearly.

The Revenue is expected to grow by 21.34% on average over the next years. This is a very strong growth

EPS Next Y-23.06%

EPS Next 2Y-16.27%

EPS Next 3Y-11.5%

EPS Next 5Y-10.08%

Revenue Next Year9.54%

Revenue Next 2Y-10.23%

Revenue Next 3Y-8.6%

Revenue Next 5Y21.34%

3.3 Evolution

More info and screens

Find the best growth stocks

Show best growing peers

4. Valuation

4.1 Price/Earnings Ratio

TNGX reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.

Also next year TNGX is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.

		Industry Rank	Sector Rank
PE	N/A
Fwd PE	N/A

4.2 Price Multiples

		Industry Rank	Sector Rank
P/FCF	N/A
EV/EBITDA	N/A

4.3 Compensation for Growth

A cheap valuation may be justified as TNGX's earnings are expected to decrease with -11.50% in the coming years.

PEG (NY)N/A

PEG (5Y)N/A

EPS Next 2Y-16.27%

EPS Next 3Y-11.5%

More info and screens

Show best valued peers

5. Dividend

5.1 Amount

TNGX does not give a dividend.

		Industry Rank	Sector Rank
Dividend Yield	N/A

More info and screens

Find the best dividend stocks

Show peers with best dividend

TANGO THERAPEUTICS INC

NASDAQ:TNGX (11/6/2024, 8:00:00 PM)

Premarket: 3.26 +0.02 (+0.62%)

3.24

-1.94 (-37.45%)

Chartmill FA Rating

GICS SectorHealth Care

GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences

GICS IndustryBiotechnology

Earnings (Last)

Earnings (Next)

Inst Owners

Inst Owner Change

Ins Owners

Ins Owner Change

Market Cap347.13M

Analysts

Price Target

Dividend

		Industry Rank	Sector Rank
Dividend Yield	N/A

Dividend Growth(5Y)

Div Incr Years

Div Non Decr Years

Ex-Date

Surprises & Revisions

EPS beat(2)

Avg EPS beat(2)

Min EPS beat(2)

Max EPS beat(2)

EPS beat(4)

Avg EPS beat(4)

Min EPS beat(4)

Max EPS beat(4)

EPS beat(8)

Avg EPS beat(8)

EPS beat(12)

Avg EPS beat(12)

EPS beat(16)

Avg EPS beat(16)

Revenue beat(2)

Avg Revenue beat(2)

Min Revenue beat(2)

Max Revenue beat(2)

Revenue beat(4)

Avg Revenue beat(4)

Min Revenue beat(4)

Max Revenue beat(4)

Revenue beat(8)

Avg Revenue beat(8)

Revenue beat(12)

Avg Revenue beat(12)

Revenue beat(16)

Avg Revenue beat(16)

PT rev (1m)

PT rev (3m)

EPS NQ rev (1m)

EPS NQ rev (3m)

EPS NY rev (1m)

EPS NY rev (3m)

Revenue NQ rev (1m)

Revenue NQ rev (3m)

Revenue NY rev (1m)

Revenue NY rev (3m)

Valuation

		Industry Rank	Sector Rank
PE	N/A
Fwd PE	N/A
P/S
P/FCF
P/OCF
P/B
P/tB
EV/EBITDA

EPS(TTM)

EPS(NY)

Fwd EY

FCF(TTM)

FCFY

OCF(TTM)

OCFY

SpS

BVpS

TBVpS

PEG (NY)N/A

PEG (5Y)N/A

Profitability

		Industry Rank	Sector Rank
ROA	-30.54%
ROE	-47.03%
ROCE
ROIC
ROICexc
ROICexgc
OM	N/A
PM (TTM)	N/A
GM	N/A
FCFM

ROA(3y)

ROA(5y)

ROE(3y)

ROE(5y)

ROIC(3y)

ROIC(5y)

ROICexc(3y)

ROICexc(5y)

ROICexgc(3y)

ROICexgc(5y)

ROCE(3y)

ROCE(5y)

ROICexcg growth 3Y

ROICexcg growth 5Y

ROICexc growth 3Y

ROICexc growth 5Y

OM growth 3Y

OM growth 5Y

PM growth 3Y

PM growth 5Y

GM growth 3Y

GM growth 5Y

F-Score

Asset Turnover0.11

Health

		Industry Rank	Sector Rank
Debt/Equity	0
Debt/FCF
Debt/EBITDA
Cap/Depr
Cap/Sales
Interest Coverage
Cash Conversion
Profit Quality
Current Ratio	7.49
Quick Ratio	7.49
Altman-Z

F-Score

WACC

ROIC/WACC

Cap/Depr(3y)

Cap/Depr(5y)

Cap/Sales(3y)

Cap/Sales(5y)

Profit Quality(3y)

Profit Quality(5y)

High Growth Momentum

Growth

EPS 1Y (TTM)-6.31%

EPS 3YN/A

EPS 5Y

EPS Q2Q%

EPS Next Y-23.06%

EPS Next 2Y

EPS Next 3Y

EPS Next 5Y

Revenue 1Y (TTM)46.93%

Revenue growth 3YN/A

Revenue growth 5Y

Sales Q2Q%

Revenue Next Year

Revenue Next 2Y

Revenue Next 3Y

Revenue Next 5Y

EBIT growth 1Y

EBIT growth 3Y

EBIT growth 5Y

EBIT Next Year

EBIT Next 3Y

EBIT Next 5Y

FCF growth 1Y

FCF growth 3Y

FCF growth 5Y

OCF growth 1Y

OCF growth 3Y

OCF growth 5Y

TANGO THERAPEUTICS INC (TNGX)

1. Profitability

1.1 Basic Checks

1.2 Ratios

1.3 Margins

More info and screens

2. Health

2.1 Basic Checks

2.2 Solvency

2.3 Liquidity

More info and screens

3. Growth

3.1 Past

3.2 Future

3.3 Evolution

More info and screens

4. Valuation

4.1 Price/Earnings Ratio

4.2 Price Multiples

4.3 Compensation for Growth

More info and screens

5. Dividend

5.1 Amount

More info and screens